Susan Bobulsky Biography and Net Worth

Chief Commercial Officer, MRD of Adaptive Biotechnologies

Susan Bobulsky is the Chief Commercial Officer, MRD, at Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Before this, she served in commercial and strategic planning roles of ascending responsibility since joining Adaptive in September 2014. Prior to joining Adaptive, Susan was an Associate Principal with ZS Associates, a healthcare management consulting firm, where she worked for nine years specializing in commercialization strategy and execution for therapeutic and diagnostic products. Susan holds an MBA from the Stanford Graduate School of Business and a BS in Science, Technology and Society from Stanford University.

What is Susan Bobulsky's net worth?: The estimated net worth of Susan Bobulsky is at least $5.63 million as of March 11th, 2026. Ms. Bobulsky owns 427,775 shares of Adaptive Biotechnologies stock worth more than $5,633,797 as of March 16th. This net worth estimate does not reflect any other assets that Ms. Bobulsky may own. Learn More about Susan Bobulsky's net worth.
How old is Susan Bobulsky?: Ms. Bobulsky is currently 43 years old. There are 6 older executives and no younger executives at Adaptive Biotechnologies. The oldest executive at Adaptive Biotechnologies is Ms. Stacy L. Taylor, Senior VP, General Counsel & Corporate Secretary, who is 64 years old. Learn More on Susan Bobulsky's age.
How do I contact Susan Bobulsky?: The corporate mailing address for Ms. Bobulsky and other Adaptive Biotechnologies executives is 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102. Adaptive Biotechnologies can also be reached via phone at (206) 659-0067 and via email at [email protected]. Learn More on Susan Bobulsky's contact information.
Has Susan Bobulsky been buying or selling shares of Adaptive Biotechnologies?: During the last quarter, Susan Bobulsky has sold $544,421.46 in Adaptive Biotechnologies stock. Most recently, Susan Bobulsky sold 41,338 shares of the business's stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $13.17, for a transaction totalling $544,421.46. Following the completion of the sale, the insider now directly owns 427,775 shares of the company's stock, valued at $5,633,796.75. Learn More on Susan Bobulsky's trading history.
Who are Adaptive Biotechnologies' active insiders?: Adaptive Biotechnologies' insider roster includes R. Adams (COO), Lance Baldo (Insider), Sharon Benzeno (Insider), Susan Bobulsky (Chief Commercial Officer, MRD), Chad Cohen (CFO), Egon Durban (Director), David Goel (Director), Michelle Griffin (Director), Robert Hershberg (Director), Francis Lo (Insider), Peter Neupert (Director), Jyoti Palaniappan (SVP), Kyle Piskel (CFO), Chad Robins (CEO), Chad Robins (CEO), Harlan Robins (Insider), Julie Rubinstein (President), and Stacy Taylor (SVP). Learn More on Adaptive Biotechnologies' active insiders.
Are insiders buying or selling shares of Adaptive Biotechnologies?: During the last twelve months, insiders at the sold shares 46 times. They sold a total of 3,638,870 shares worth more than $55,866,670.20. The most recent insider tranaction occured on March, 13th when COO Julie Rubinstein sold 19,060 shares worth more than $247,017.60. Insiders at Adaptive Biotechnologies own 6.4% of the company. Learn More about insider trades at Adaptive Biotechnologies.
Information on this page was last updated on 3/13/2026.

Susan Bobulsky Insider Trading History at Adaptive Biotechnologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/11/2026	Sell	41,338	$13.17	$544,421.46	427,775
9/29/2020	Sell	10,000	$50.00	$500,000.00	10,000

Susan Bobulsky Buying and Selling Activity at Adaptive Biotechnologies

Adaptive Biotechnologies Company Overview

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Today's Range

Now: $13.25

$13.25

50 Day Range

MA: $16.55

$12.45

$19.23

2 Week Range

Now: $13.25

$6.68

$20.76

Volume

2,026 shs

Average Volume

2,006,219 shs

Market Capitalization

$2.04 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.19

Susan Bobulsky Biography and Net Worth

What is Susan Bobulsky's net worth?

How old is Susan Bobulsky?

How do I contact Susan Bobulsky?

Has Susan Bobulsky been buying or selling shares of Adaptive Biotechnologies?

Who are Adaptive Biotechnologies' active insiders?

Are insiders buying or selling shares of Adaptive Biotechnologies?